CAFE Comparison of Atypicals in First Episode of Psychosis

AstraZeneca

Overview

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Schizophrenia Psychotic Disorders Mental Health Mental Disorders

Interventions

Olanzapine, risperidoneDRUG

Eligibility

Sex: ALLMin age: 16 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months * Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months) * Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics Exclusion Criteria: * Patients with history of psychotic disorder with recovery period of at least 3 months * Female patients who are pregnant or nursing * Patients with a known history of mental retardation

Locations (26)

Unnamed facility

Stanford, California, United States

Unnamed facility

Miami, Florida, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.